Contact
Please use this form to send email to PR contact of this press release:
Liminatus Pharma (LIMN) Advances CD47 Immunotherapy with Enhanced Safety Profile and Korean Clinical Collaboration
TO:
Chris Kim
Liminatus Pharma, Inc
+1 213-273-5453